A First-in-man Phase I/II Single-agent Open-label Dose-escalation Study of Every Three-week Dosing of Oral ONC201 in Patients With Advanced Solid Tumors

Trial Profile

A First-in-man Phase I/II Single-agent Open-label Dose-escalation Study of Every Three-week Dosing of Oral ONC201 in Patients With Advanced Solid Tumors

Withdrawn prior to enrolment
Phase of Trial: Phase I/II

Latest Information Update: 24 Dec 2015

At a glance

  • Drugs ONC 201 (Primary)
  • Indications Advanced breast cancer; Colorectal cancer; Glioblastoma; Non-small cell lung cancer
  • Focus Adverse reactions; First in man; Therapeutic Use
  • Sponsors Oncoceutics
  • Most Recent Events

    • 07 Jun 2017 Biomarkers information updated
    • 21 Dec 2015 Status changed from recruiting to withdrawn prior to enrolment as reported by ClinicalTrials.gov record.
    • 25 Mar 2015 Status changed from not yet recruiting to recruiting according to an Oncoceutics media release.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top